| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA883: Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma |
|
Medicine details |
|
| Medicine name | tafasitamab (Minjuvi®) |
| Formulation | 200 mg powder for concentrate for solution for infusion |
| Reference number | 4443 |
| Indication | In combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) |
| Company | Incyte Biosciences |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/07/2021 |
| NICE guidance | |